糖皮质激素受体对多发性骨髓瘤的疗效预测

STUDY OF GLUCOCORTICOID RECEPTOR IN PREDICTING CHEMOTHERAPEUTIC EFFECT ON MULTIPLE MYELOMA

本文研究３８例多发性骨髓瘤和１５例正常骨髓细胞糖皮质激素受体水平，前者 为１４７１９±７７８５位点细胞，后者 为６７５０±１７０５位点细胞，多发性骨髓瘤糖皮质激素受体水平明显高于正常水平，Ｐ＜０．０１，ｔ＝３．５２。研究发现，多发性骨髓瘤糖皮质激素受体水平与化疗疗效无相关性，即糖皮质激素受体水平不能预测多发性骨髓瘤的疗效。

Glucocorticoid receptor(GR)levels of bone marrow cells in 38 patients with Multiple Myeloma(MM) and 15 subjects with normal bone marrow were studied. x±s in the former was 14719± 7785sites/cell,that of the latter 6750± 1705. The former was much higher than the latter (P<0. 01, t= 3. 52).The results suggest that there is no correlation between GR level of MM and chemotherapeutic effect,that is,GR levels does not predict chemotherapeutic effect on patients with Multiple Myeloma.